**Background**
Epilepsy is a chronic neurological disorder characterized by recurrent, unprovoked seizures, which can significantly impact a patient’s quality of life and cognitive function. Partial seizures, which originate in a localized area of one hemisphere of the brain, require effective adjunctive pharmacological treatment to reduce seizure frequency and improve clinical outcomes. Voltage-gated sodium channels play a critical role in the generation and propagation of neuronal hyperexcitability, making them primary targets for the development of anti-epileptic drugs. While traditional medications like carbamazepine have been widely used, there is a continuous need for agents with improved safety profiles and reduced adverse effects. In this context, we will introduce an oral anticonvulsant – Eslicarbazepine.
**Definition**
Eslicarbazepine is an oral anticonvulsant and anti-epileptic drug that serves as the active metabolite of the prodrug eslicarbazepine acetate. It functions as a dual inhibitor of $\beta$-Secretase and voltage-gated sodium channels.
**In Vivo Studies**
Regarding the Eslicarbazepine biological activity, this compound is chemically related to carbamazepine but is designed to offer a more favorable safety profile for patients. Eslicarbazepine in vivo studies indicate its efficacy as an anti-epileptic agent indicated for the adjunctive treatment of partial seizures. Furthermore, enzoinformatics studies have highlighted the potential of eslicarbazepine acetate as a dual inhibitor of $\beta$-Secretase and voltage-gated sodium channels, suggesting a possible therapeutic linkage between the treatment of epilepsy and Alzheimer’s disease. For researchers requiring specific Eslicarbazepine technical information, the compound possesses a molecular weight of 254.29 and a molecular formula of $\text{C}_{15}\text{H}_{14}\text{N}_2\text{O}_2$. In conclusion, Eslicarbazepine is a potent dual inhibitor of $\beta$-Secretase and voltage-gated sodium channels with significant potential in the management of partial seizures.
Keywords
Eslicarbazepine, 104746-04-5, BIA 2-194, Beta-secretase, Sodium Channel, BACE, β-Secretase, Na channels, Na+ channels, Inhibitor, inhibitor, inhibit
References
[1] Finelli E, et al. Patch testing in a case of eslicarbazepine and carbamazepine induced cutaneous reaction. Eur Ann Allergy Clin Immunol. 2018 Sep;50(5):229-231.
[2] Sibhghatulla Shaikh, et al. Aptiom (Eslicarbazepine Acetate) as a Dual Inhibitor of β-Secretase and Voltage-Gated Sodium Channel: Advancement in Alzheimer’s Disease-Epilepsy Linkage via an Enzoinformatics Study. CNS & Neurological Disorders Drug Targets Volume 13 , Issue 7 , 2014.